Imai H, et al. - Researchers prospectively evaluated elderly (age ≥70 years) chemotherapy-naive non-small-cell lung cancer (NSCLC) patients with EGFR (epidermal growth factor receptor) mutations (exon 19 deletion or exon 21 L858R mutation), to determine the efficacy and safety of afatinib in these subjects. At a dose of 30 mg per day, initial treatment with afatinib was administered to all patients. In this study, the efficacy and feasibility of first-line chemotherapy with afatinib at 30 mg/day was verified for the fist time in elderly patients with advanced NSCLC harboring sensitive EGFR mutations. The adverse events (AEs) that were commonly experienced by patients included diarrhea, rash/acne, and anemia. Major grade 3 or higher toxicities included diarrhea (12.5%), mucositis (7.5%), and pneumonitis (7.5%). Overall, first-line afatinib of 30 mg/day could be a treatment option in this patient population.